Dr. Hambleton also serves on the Board of Directors at Accent Therapeutics, SpringWorks Therapeutics, and she previously served on the Board of Directors of Arch Oncology where she was also Interim Chief Executive Officer. Previously, she was the Chief Medical Officer and Head of Development at IDEAYA Biosciences, an oncology medicine company. Prior to IDEAYA, she was Vice President and Head of U.S. Medical at Bristol-Myers Squibb. She has also served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics, Vice President of Clinical Development at Clovis Oncology, and held increasing roles of responsibility in BioOncology at Roche/Genentech, most recently as Global Cluster Head and Global Group Medical Director. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, and served on the faculty there from 1993 to 2003. Dr. Hambleton received a B.S. in Nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine. She is board-certified in Hematology and Internal Medicine.
Julie Hambleton, M.D.